cathepsin L5 does not exhibit substantial catalytic activity against substrates containing proline in the P2 position (thereby distinguished from Fasciola cathepsin L1, L2 and L3)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
cathepsin L5 does not exhibit substantial catalytic activity against substrates containing proline in the P2 position (thereby distinguished from Fasciola cathepsin L1, L2 and L3)
no activity with PFR-7-amido-4-methylcoumarin, Boc-DPR-7-amido-4-methylcoumarin, Boc-AGPR-7-amido-4-methylcoumarin, Boc-VPR-7-amido-4-methylcoumarin, D-Val-Leu-Arg-7-amido-4-methylcoumarin, Boc-VLK-7-amido-4-methylcoumarin, and benzoyl-FVR-7-amido-4-methylcoumarin
no activity with PFR-7-amido-4-methylcoumarin, Boc-DPR-7-amido-4-methylcoumarin, Boc-AGPR-7-amido-4-methylcoumarin, Boc-VPR-7-amido-4-methylcoumarin, D-Val-Leu-Arg-7-amido-4-methylcoumarin, Boc-VLK-7-amido-4-methylcoumarin, and benzoyl-FVR-7-amido-4-methylcoumarin
the enzyme is secreted. Cathepsin L5 (FhCL5) constitutes approximately 7% and 5-10% of the secreted protease content of immature and adult flukes, respectively
the mutation results in an increased preference for substrates containing proline at P2. The mutant shows increased Km values for benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin and tosyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin compared to the wild type enzyme, but show increased catalytic efficiency for tosyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin
gene FhpCL5, DNA and amino acid sequence determination and analysis, sequence comparisons of rFhpCLs, recombinant expression of His-tagged enzyme in Escherichia coli
analysis of the diagnostic values of the three different clades of cathepsin Ls, FhCL1, FhCL2, and FhCL5, from adult flukes in an ELISA, test of sera from sheep and cattle naturally infected with Fasciola hepatica, of cross-reactive antibodies, overview. For sheep sera, the sensitivity is 100% for the three rFhpCLs, while for cattle sera, the highest sensitivity is obtained using rFhpCL2 (97%), being equal for both rFhpCL1 and rFhpCL5 (87.9%), after adjusting cut-offs for maximum specificity
vaccination of rats with recombinant zymogen and subsequent challenge with Fasciola hepatica metercercariae. Vaccination results in significantly smaller and fewer flukes than in controls. Maximal protection of 83% is seen in the group vaccinated with cathepsin B and cathepsin L5 in combinantion
Fasciola hepatica infection continues to be a major problem in the agriculture sector, particularly in sheep and cattle. Cathepsin L and B proteases are major components of the excretory/secretory material of the parasite, and their roles in several important aspects of parasite invasion and survival has led to their use as targets in rational vaccine design. Recombinant versions of cathepsin L5 and cathepsin B2 produced in yeast are used in combination in a commercial adjuvant preparation to vaccinate sheep. Intramuscular and intranasal forms of administration are applied, and sheep are subsequently challenged with 150 Fasciola hepatica metacercariae. Intramuscular vaccination is able to induce a strong systemic antibody response against both antigens, but fails to confer significant protection. Conversely, no elevated antibody response is detected against the vaccine antigens following nasal vaccination, but a reduction in parasite egg viability (above 92%) and a statistically significant, predominantly adjuvant-mediated reduction in worm burdens is observed
cathepsin L5, cathepsin L1g and cathepsin B are expressed in yeast from cDNA clones isolated from adult, metacercariae and newly excysted juvenile flukes respectively. Each is used solely or in combination to vaccinate rats that are subsequently challenged with Fasciola hepatica metercercariae. Each protein induces an immune response, and all groups vaccinated with recombinant protein yield significantly fewer and smaller flukes than the control group. Maximal protection of 83% is seen in the group vaccinated with cathepsin B and cathepsin L5 in combination
Fasciola hepatica infection continues to be a major problem in the agriculture sector, particularly in sheep and cattle. Cathepsin L and B proteases are major components of the excretory/secretory material of the parasite, and their roles in several important aspects of parasite invasion and survival has led to their use as targets in rational vaccine design. Recombinant versions of cathepsin L5 and cathepsin B2 produced in yeast are used in combination in a commercial adjuvant preparation to vaccinate sheep. Intramuscular and intranasal forms of administration are applied, and sheep are subsequently challenged with 150 Fasciola hepatica metacercariae. Intramuscular vaccination is able to induce a strong systemic antibody response against both antigens, but fails to confer significant protection. Conversely, no elevated antibody response is detected against the vaccine antigens following nasal vaccination, but a reduction in parasite egg viability (above 92%) and a statistically significant, predominantly adjuvant-mediated reduction in worm burdens is observed
Siyaguna, S.; Spithill, T.W.: Pike, R.N.: A single amino acid substitution affects substrate specificity in cysteine proteinases from Fasciola hepatica
Raadsma, H.W.; Kingsford, N.M.; Suharyanta; Spithill, T.W.; Piedrafita, D.
Host responses during experimental infection with Fasciola gigantica and Fasciola hepatica in Merino sheep II. Development of a predictive index for Fasciola gigantica worm burden
Intranasal delivery of a formulation containing stage-specific recombinant proteins of Fasciola hepatica cathepsin L5 and cathepsin B2 triggers an anti-fecundity effect and an adjuvant-mediated reduction in fluke burden in sheep